Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol

• Published in: Advances in therapy Vol. 36; no. 9; pp. 2506 - 2514
• Main Authors: Quaranta, Luciano, Riva, Ivano, Biagioli, Elena, Rulli, Erica, Rulli, Eliana, Poli, Davide, Legramandi, Lorenzo
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-09-2019
• Subjects: Cardiology; Endocrinology; Health technology assessment; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Pharmacology/Toxicology; Rheumatology; Study Protocol; Prostaglandin analogue; Randomized clinical trial; Ophthalmology; Coenzyme Q10; Open-angle glaucoma; Vitamin E
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-019-01023-3

Introduction
The CoQun
®
study is a multicenter, controlled trial aimed to evaluate the neuroprotective effects of Coqun
®
, an ophthalmic solution of Coenzyme q10 (CoQ10) and Vitamin E (VitE), in patients affected by primary open-angle glaucoma (POAG). Pre-clinical studies and small non-controlled clinical trials have previously shown a potential role of CoQ10 and VitE in glaucoma neuroprotection, both in vitro and in vivo.
Methods
Randomized, parallel arm, multicenter, double-blind study. POAG patients with an IOP ranging from 17 to 21 mm Hg on monotherapy with a prostaglandin analogue (PGA) will be considered for study enrollment. Inclusion criteria will be visual field (VF) mean deviation between − 4 and − 10 dB and VF Pattern Standard Deviation between 4 and 10 dB. Eligible patients will be randomized to receive CoQun
®
(Arm A) or placebo (Arm B), in addition to PGA monotherapy.
Planned Outcomes
Primary outcome will be time to progression, defined as the time between the baseline visit and the visit with confirmed VF progression. A total of 612 patients are planned to be enrolled, to detect a hazard ratio of 0.65, with a power of 80% and an alpha error of 0.05 (two-sided). For study power calculation, 10% non-evaluable patients are assumed. This is the first study investigating, in a randomized, double-blind and controlled fashion, the neuroprotective effects of CoQ10 and VitE in POAG patients.
Trial Registration
ClinicalTrials.gov identifier, NCT03611530.